Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251

On Wednesday, Zymeworks Inc. ZYME released fourth-quarter financial results. The company reported an earnings loss of 31 cents per share, missing the consensus loss of 3 cents.Sales came at $31.03 million, missing the consensus of$45.2 million.In its fourth-quarter earnings results, Zymeworks said it is increasing its development efforts on plans for ZW251.“Based on our encouraging preclinical results and the unique potential opportunity to help hepatocellular carcinoma patients, we have decided to reprior ...